SAN ANTONIO, TX, March 17, 2026
bioAffinity Technologies, Inc. has released a new clinical case study demonstrating how its CyPath® Lung noninvasive diagnostic test significantly improves clinical decision-making in patients with suspected lung cancer, helping physicians avoid unnecessary invasive procedures while maintaining diagnostic accuracy. The case highlights a 71-year-old high-risk patient with multiple pulmonary nodules, where the test result indicating “unlikely malignancy” enabled clinicians to safely defer invasive biopsy procedures, ultimately confirming a benign outcome through follow-up imaging.
Noninvasive Test Enhances Diagnostic Confidence
The case study underscores the growing importance of noninvasive diagnostic technologies in lung cancer management, particularly in patients presenting with small indeterminate nodules detected via low-dose CT scans. In this instance, a 7 mm pulmonary nodule, often associated with increased malignancy risk, would typically trigger invasive diagnostic interventions such as bronchoscopy or biopsy. However, the CyPath® Lung test provided a negative result, supporting a more conservative clinical approach.
This outcome allowed both physician and patient to opt for active surveillance instead of immediate invasive procedures, reducing patient anxiety and avoiding potential complications. The follow-up CT scan conducted three months later confirmed that the suspicious nodules had resolved, validating the clinical utility of CyPath® Lung in risk stratification and patient management. Such advancements are particularly relevant in modern healthcare systems where precision diagnostics and patient-centered care are critical priorities.
Strong Clinical Performance Metrics Support Adoption
Advertisement
The effectiveness of CyPath® Lung is further supported by robust clinical performance data, demonstrating 92% sensitivity, 87% specificity, and 88% overall accuracy in detecting lung cancer in nodules smaller than 20 mm. These metrics highlight the test’s ability to accurately differentiate between malignant and benign conditions, a key challenge in pulmonary diagnostics.
The technology behind CyPath® Lung integrates advanced flow cytometry with proprietary artificial intelligence (AI) to analyze sputum samples and identify cellular markers associated with malignancy. Additionally, the use of a fluorescent porphyrin compound selectively absorbed by cancer-related cells enhances detection capabilities, positioning the test as a highly innovative diagnostic tool in oncology.
This combination of AI-driven analytics and noninvasive sampling aligns with the broader industry trend toward early detection and minimally invasive diagnostics, which are essential for improving survival outcomes in lung cancer, one of the leading causes of cancer-related mortality worldwide.
Impact on Clinical Practice and Healthcare Costs
Beyond diagnostic accuracy, the case study highlights the potential of CyPath® Lung to reduce healthcare costs and improve clinical workflows by minimizing unnecessary procedures. Invasive biopsies not only carry risks such as bleeding and infection but also contribute significantly to healthcare expenditures. By enabling clinicians to confidently delay or avoid such interventions, CyPath® Lung supports more efficient resource utilization.
The test is currently offered as a Laboratory Developed Test (LDT) under the oversight of the Clinical Laboratory Improvement Amendments (CLIA), ensuring compliance with regulatory standards for laboratory testing. This regulatory framework provides assurance of quality, reliability, and clinical validity, which are essential for adoption in routine medical practice.
Furthermore, the integration of CyPath® Lung into diagnostic pathways represents a shift toward personalized medicine, where treatment decisions are guided by patient-specific data rather than generalized protocols. This approach enhances both clinical outcomes and patient experience, reinforcing the value of innovative diagnostic solutions in modern healthcare.
The newly released case study from bioAffinity Technologies demonstrates that CyPath® Lung is a powerful noninvasive diagnostic tool capable of improving clinical decision-making, reducing unnecessary invasive procedures, and delivering high diagnostic accuracy in lung cancer detection. As healthcare systems continue to prioritize early detection, cost efficiency, and patient safety, technologies like CyPath® Lung are poised to play a critical role in transforming the diagnostic landscape. This development represents a significant advancement in medical technology and precision diagnostics, with strong implications for clinicians, patients, and healthcare providers.
Source: bioaffinity technologies press release
